Retinopathy of prematurity: Do we still have a problem? The Charles L. Schepens lecture

Archives of Ophthalmology

Volumn 129, Issue 8, 2011, Pages 1083-1086

  Tasman, William ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID;

BLINDNESS; CLINICAL ASSESSMENT; CONFERENCE PAPER; EPIDEMIC; HEALTH SERVICE; HUMAN; INFORMATION RETRIEVAL; INTENSIVE CARE UNIT; INTERVIEW; LOW BIRTH WEIGHT; LOW LEVEL LASER THERAPY; MEDICAL SCHOOL; OUTPATIENT CARE; PATIENT REFERRAL; PHYSICIAN; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; SCHOOL; SCREENING; UNITED STATES;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; INFANT, NEWBORN; LASER COAGULATION; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051566131     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.192     Document Type: Conference Paper

References (26)

1. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens, I: preliminary report. Am J Ophthalmol. 1942;25:203-204.
2. Crosse VM, Evans PJ. Prevention of retrolental fibroplasia. AMA Arch Ophthalmol. 1952;48(1):83-87.
3. Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK. Childhood blindness. J AAPOS. 1999;3(1):26-32.
4. Gilbert C, Fielder A, Gordillo L, et al International NO-ROP Group. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005;115(5):e518-e525. (Pubitemid 43843209)
5. Gilbert C. Retinopathy of prematurity: epidemiology. J Community Eye Health. 1997;10(22):22-24. http://www.cehjournal.org/0953-6833/10/jceh-10-22- 022.html. Accessed May 27, 2011.
6. Reddy SC, Tan BC. Causes of childhood blindness in Malaysia: results from a national study of blind school students. Int Ophthalmol. 2001;24(1):53-59. (Pubitemid 34256678)
7. Haddad MA, Sei M, Sampaio MW, Kara-José N. Causes of visual impairment in children: a study of 3,210 cases. J Pediatr Ophthalmol Strabismus. 2007;44(4):232-240. (Pubitemid 47280418)
8. Rahi JS, Sripathi S, Gilbert CE, Foster A. Childhood blindness in India: causes in 1318 blind school students in nine states. Eye (Lond). 1995;9(pt 5):545-550.
9. Kello AB, Gilbert C. Causes of severe visual impairment and blindness in children in schools for the blind in Ethiopia. Br J Ophthalmol. 2003;87(5):526-530. (Pubitemid 36535315)
10. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: Snellen visual acuity and structural outcome at 5 1/2 years after randomization. Arch Ophthalmol. 1996;114(4):417-424.
11. Good WV, Hardy RJ, Dobson V, et al Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity Study. Pediatrics. 2005;116(1):15-23.
12. Tasman W, Patz A, McNamara JA, Kaiser RS, Trese MT, Smith BT. Retinopathy of prematurity: the life of a lifetime disease. Am J Ophthalmol. 2006;141(1):167-174.
13. Baker PS, Tasman W. Optical coherence tomography imaging of the fovea in retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2010;41(2):201-206.
14. Baker PS, Tasman W. Myopia in adults with retinopathy of prematurity. Am J Ophthalmol. 2008;145(6):1090-1094.
15. US Census Bureau Estimates. US Census Bureau Web site. http://www.census.gov/popest/estimates.html. Accessed May 27, 2011.
16. US Census Bureau International Data Base (IDB). http://www.census.gov/ ipc/www/idb/. Accessed May 27, 2011.
17. Hurley BR, McNamara JA, Fineman MS, et al. Laser treatment for retinopathy of prematurity: evolution in treatment technique over 15 years. Retina. 2006;26(7)(suppl):S16-S17. (Pubitemid 44341907)
18. Quiroz-Mercado H, Ustariz-González O, Martinez-Castellanos MA, Covarrubias P, Dominguez F, Sanchez-Huerta V. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Semin Ophthalmol. 2007;22(2):109-125. (Pubitemid 46918882)
19. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28(6):831-838.
20. Sakurai K, Akiyama H, Shimoda Y, Yoshida I, Kurabayashi M, Kishi S. Effect of intravitreal injection of high-dose bevacizumab in monkey eyes. Invest Ophthalmol Vis Sci. 2009;50(10):4905-4916.
21. Silverman WA. Retrolental Fibroplasia: A Modern Parable. New York, NY: Grune & Stratton; 1980.
22. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;362(21):1959-1969.
23. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695.e1-1695.e15.
24. Sears JE. Anti-vascular endothelial growth factor and retinopathy of prematurity. Br J Ophthalmol. 2008;92(11):1437-1438.
25. Sears JE, Pietz J, Sonnie C, Dolcini D, Hoppe G. A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity. Ophthalmology. 2009;116(3):513-518.
26. Darlow BA, Gilbert C, Quinn GE, et al. Promise and potential pitfalls of anti-VEGF drugs in retinopathy of prematurity. Br J Ophthalmol. 2009;93(7):986.